Table 2 Association between MALAT1 expression and overall survival
Survival analysis | Subgroup | Studies (n) | Patients (n) | HR (95% CI) | P | Heterogeneity (I2, P) |
|---|---|---|---|---|---|---|
Univariate | Overall | 15 | 1869 | 2.296 (1.716–3.072) | 0.000 | 67.6%, 0.000 |
Region | ||||||
China | 12 | 1209 | 2.793 (2.310–3.376) | 0.000 | 0.0%, 0.924 | |
Other | 3 | 660 | 1.164 (0.577–2.346) | 0.672 | 83.5%, 0.002 | |
Cancer type | ||||||
Estrogen-dependent carcinoma | 2 | 198 | 3.296 (2.027–5.358) | 0.000 | 22.9%, 0.255 | |
Urological carcinoma | 2 | 226 | 3.184 (2.072–4.892) | 0.000 | 0.0%, 0.739 | |
Glioma | 2 | 258 | 2.750 (1.839–4.111) | 0.000 | 0.0%, 0.553 | |
Digestive carcinoma | 6 | 633 | 1.750 (0.974–3.143) | 0.061 | 79.7%, 0.000 | |
Other | 3 | 554 | 2.154 (1.471–3.154) | 0.000 | 0.0%, 0.484 | |
Sample size | ||||||
Sample < 100 | 5 | 333 | 2.443 (1.655–3.608) | 0.000 | 0.0%, 0.752 | |
Sample > 100 | 10 | 1536 | 2.203 (1.516–3.202 | 0.000 | 77.9%, 0.000 | |
Multivariate | Overall | 18 | 1891 | 2.298 (1.953–2.704) | 0.000 | 17.2%, 0.248 |
Region | ||||||
China | 17 | 1817 | 2.327 (1.968–2.751) | 0.000 | 20.6%, 0.213 | |
Other | 1 | 74 | 1.880 (0.957–3.695) | 0.067 | – | |
Cancer type | ||||||
Estrogen-dependent carcinoma | 2 | 198 | 2.656 (1.560–4.523) | 0.000 | 0.0%, 0.457 | |
Urological carcinoma | 3 | 321 | 1.952 (1.189–3.204) | 0.008 | 51.4%, 0.128 | |
Glioma | 4 | 430 | 2.315 (1.643–3.263) | 0.000 | 0.0%, 0.534 | |
Digestive carcinoma | 7 | 706 | 2.451 (1.862–3.227) | 0.000 | 45.4%, 0.089 | |
Other | 2 | 236 | 2.383 (1.449–3.920) | 0.001 | 3.3%, 0.309 | |
Sample size | ||||||
Sample < 100 | 7 | 528 | 2.017 (1.520–2.677) | 0.000 | 10.4%, 0.350 | |
Sample > 100 | 11 | 1363 | 2.451 (2.009–2.990) | 0.000 | 20.7%, 0.246 | |